13 completed, 6 recruiting, 2 terminated, 2 unknown. 5 Phase 2, 3 Not applicable, 3 Phase 3, 2 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Terminated 2, Active not recruiting 1 |
| Not applicable | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow Myoclonus: new trials by email Literature Review of Myoclonus trials Research Report on Myoclonus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Registry and Natural History of Epilepsy-Dyskinesia Syndromes Epilepsy-Dyskinesia, Epilepsy | Recruiting | Boston Children's Hospital | 700 | 2025-06-01 | 2025-08-17 | |
| High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3) Ambroxol - Gaucher Disease, Type 3 | Not applicable | Completed | Agyany Pharma LTD | 12 | 2025-03-01 | 2026-08-24 |
| Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) Progressive Myoclonus Epilepsy Type 1, EPM1 | Recruiting | Boston Children's Hospital | 200 | 2024-10-10 | 2026-03-18 | |
| A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes Epilepsy in Children, Dyskinesias | Recruiting | Boston Children's Hospital | 500 | 2024-07-01 | 2026-03-18 | |
| Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection Remifentanil - Etomidate, Myoclonus | Not applicable | Unknown | Yangzhou University | 70 | 2023-03-01 | 2023-03-06 |
| Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia DystoniaNet-based diagnosis of isolated dystonia - Dystonia, Drug Induced Dystonia | Not applicable | Recruiting | Massachusetts Eye and Ear Infirmary | 1000 | 2022-06-01 | 2025-12-02 |
| Electrophysiological Characteristics and Anatomical Differentiation of Epileptic and Non-epileptic Myoclonus. Somatosensory evoked potential - Myoclonus, Evoked Potential | Completed | Mansoura University Hospital | 50 | 2018-11-01 | 2020-01-22 | |
| Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus Low-dose Dexmedetomidine, High-dose dexmedetomidine, normal saline - Myoclonus | Phase 4 | Unknown | Tang-Du Hospital | 132 | 2015-09-01 | 2015-08-10 |
| Effect of Pretreatment of Lignocaine Versus Midazolam in Prevention of Etomidate Induced Myoclonus. lignocaine, Midazolam 1 milligram Prefilled Syringe - Myoclonic Jerk | Phase 4 | Completed | Rawalpindi Medical College | 224 | 2015-01-01 | 2021-06-10 |
| Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Dexamethasone acetate, dexamethasone and cyclophosphamide, dexamethasone and rituximab - Opsoclonus Myoclonus Syndrome, Neuroblastoma | Phase 3 | Completed | Institut Curie | 102 | 2013-04-18 | 2025-02-03 |
| Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Rare Disorders, Undiagnosed Disorders | Recruiting | Sanford Health | 20000 | 2010-07-01 | 2026-10-28 | |
| Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Autoimmune Disease, Neurologic Autoimmune Disease | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2008-06-01 | 2026-02-27 |
| Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Opsoclonus-myoclonus Syndrome | Completed | National Pediatric Neuroinflammation Organization, Inc. | 400 | 2008-01-01 | 2017-05-23 | |
| Pilot Efficacy Study of T2000 in Myoclonus Dystonia T2000 - Myoclonus | Phase 2 | Terminated | Sun Pharmaceutical Industries, Inc. | 5 | 2007-08-01 | 2013-12-23 |
| Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults Brivaracetam 25 mg, Brivaracetam 50 mg, Placebo - Unverricht-Lundborg Disease | Phase 3 | Completed | UCB Pharma SA | 50 | 2006-11-01 | 2015-05-18 |
| Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults Placebo, BRV 2.5 mg, BRV 25 mg - Unverricht-Lundborg Disease | Phase 3 | Completed | UCB Pharma | 56 | 2006-11-01 | 2023-05-31 |
| Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma anti-CD20 (Rituximab) - Neuroblastoma, Opsoclonus-myoclonus | Phase 2 | Terminated | Jean M. Tersak, M.D. | 4 | 2005-07-01 | 2021-01-22 |
| Effectiveness of Rituximab in Pediatric OMS Patients. rituximab - Opsoclonus-myoclonus Syndrome, Opsoclonus | Phase 1 / Phase 2 | Completed | National Pediatric Neuroinflammation Organization, Inc. | 25 | 2005-06-01 | 2011-05-10 |
| OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease OGT 918 - Gaucher Disease | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 30 | 2002-07-05 | 2017-07-02 |
| Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders Neurological Regression, Myoclonus | Recruiting | National Human Genome Research Institute (NHGRI) | 200 | 2002-02-06 | 2026-11-12 |
Showing 20 of 24. Sign in to see all of them.
Ataxia (6) · Movement Disorders (5) · Opsoclonus-Myoclonus Syndrome (5) · Dyskinesias (4) · Nervous System Diseases (4) · Epilepsy (3) · Myoclonic Epilepsies, Progressive (3) · Neuroblastoma (3) · Unverricht-Lundborg Syndrome (3) · Autoimmune Diseases (2) · Chorea (2) · Dystonia (2) · Dystonia 12 (2) · Dystonic Disorders (2)
Neurologic Manifestations (23) · Pathological Conditions, Signs and Symptoms (22) · Signs and Symptoms (21) · Central Nervous System Diseases (20) · Dyskinesias (20) · Nervous System Diseases (20) · Brain Diseases (13) · Neurodegenerative Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Cranial Nerve Diseases (6) · Eye Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Nervous System Neoplasms (6)
Rituximab (3) · brivaracetam (2) · Ambroxol (1) · Antilymphocyte Serum (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Dexamethasone (1) · Dexmedetomidine (1) · Etomidate (1) · Etoposide (1) · Evoked Potentials, Somatosensory (1) · Lidocaine (1) · Melphalan (1) · Midazolam (1)
National Institute of Neurological Disorders and Stroke (NINDS) (5) · Boston Children's Hospital (3) · National Pediatric Neuroinflammation Organization, Inc. (2) · Agyany Pharma LTD (1) · Fred Hutchinson Cancer Center (1) · Institut Curie (1) · Jean M. Tersak, M.D. (1) · Mansoura University Hospital (1) · Massachusetts Eye and Ear Infirmary (1) · National Human Genome Research Institute (NHGRI) (1) · Rawalpindi Medical College (1) · Sanford Health (1) · Sun Pharmaceutical Industries, Inc. (1) · Tang-Du Hospital (1) · UCB Pharma (1)
United States (15) · France (3) · Canada (2) · Finland (2) · Italy (2) · Sweden (2) · Tunisia (2) · United Kingdom (2) · Austria (1) · Egypt (1) · Israel (1) · Netherlands (1) · Pakistan (1) · Reunion (1) · Russia (1)
Cynthia J Tifft, M.D. (1) · Elizabeth D Tate, FNP, MN (1) · Esmael Ahmed, MD (1) · Fizza Batool, FCPS (1) · Gudrun Schleiermacher, MD (1) · Huma Arshad Cheema, Prof. (1) · Jean M Tersak, M.D. (1) · Kristina Simonyan, MD, PhD (1) · Leona Holmberg (1) · Michael R Pranzatelli, M.D. (1) · Michael R Pranzatelli, MD (1)
PMID 21211990, PMID 26666500, PMID 33461041, PMID 12635389, PMID 12869812, PMID 19838774, PMID 20057497, PMID 20606544, PMID 22264765, PMID 23324534, PMID 23340773, PMID 23380454, PMID 23600831, PMID 23659672, PMID 23764550, PMID 24342231, PMID 30323563, PMID 32753397, PMID 36461157, PMID 36700853, PMID 38641994